Thermo Fisher Scientific Inc. 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended June 27, 2026. Thermo Fisher Scientific Inc. operates in four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company serves pharmaceutical, biotech, academic, government, industrial, and healthcare markets globally.
Key Financial Metrics (Six Months Ended June 27, 2026)
| Metric | Value (in millions) |
|---|---|
| Total Revenues | $22,999 |
| GAAP Operating Income | $3,950 |
| GAAP Operating Margin | 17.2% |
| Net Income Attributable to TFS | $3,387 |
| Diluted EPS | $9.10 |
| Free Cash Flow (Non-GAAP) | $2,503 |
| Total Debt (Carrying Value) | $42,284 |
| Cash and Cash Equivalents | $4,064 |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 8% year-over-year to $22.999 billion. Organic revenue growth was 3%, driven by a 4% impact from acquisitions and 2% from currency translation.
- Profitability: GAAP operating income rose 11% to $3.95 billion. Adjusted operating income (non-GAAP) increased 11% to $5.133 billion, with margins expanding 0.4 percentage points to 22.3% due to strong productivity improvements.
- Acquisitions: The company acquired Clario Holdings, Inc. for approximately $9.1 billion (including debt settled) in March 2026, significantly impacting the Laboratory Products and Biopharma Services segment.
- Divestiture: An agreement was reached to sell the microbiology business (Specialty Diagnostics segment) for approximately $1.075 billion, expected to close in Q3 2026.
- Cash Flow: Net cash provided by operating activities increased 56% to $3.317 billion. However, net cash used in investing activities surged to $8.797 billion, primarily due to the $8.872 billion cash outflow for the Clario acquisition.
Guidance, Outlook, and Risks
- Capital Allocation: The company repurchased $4.00 billion of common stock in the first six months of 2026. As of July 31, 2026, $1.00 billion remained available under the current $5.00 billion authorization.
- Restructuring: The company expects additional restructuring charges of approximately $220 million in 2026, primarily related to headcount reductions and facility consolidations.
- Tax Outlook: The GAAP effective tax rate for 2026 is expected to be between 9% and 11%. The adjusted tax rate is expected to be approximately 11.5%.
- Capital Expenditures: Full-year 2026 capital expenditures are expected to range between $1.9 billion and $2.1 billion.
- Risks: Key risks include integration of acquisitions, global economic conditions, supply chain disruptions, and regulatory changes. The company notes that the sale of the microbiology business is subject to regulatory approvals.
Investor Verification Checklist
- Verify the final purchase price and asset allocation for the Clario Holdings acquisition upon closing.
- Monitor the closing status and regulatory approval of the microbiology business divestiture to Astorg.
- Track the execution of the $220 million in expected additional restructuring charges.
- Review the impact of the One Big Beautiful Bill Act (OBBBA) on future tax provisions as the company transitions to 2026 tax rates.
- Assess the sustainability of the 3% organic revenue growth rate in the context of global pharma and biotech market conditions.